![](/img/cover-not-exists.png)
Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial
Ignatiadis, M., Litiere, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, KVolume:
92
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(18)30263-6
Date:
April, 2018
File:
PDF, 47 KB
english, 2018